Facial reconstruction

Search LJMU Research Online

Browse Repository | Browse E-Theses

Paclitaxel-loaded Micro or Nano Transfersome Formulation into Novel Tablets for Pulmonary Drug Delivery via Nebulization.

Khan, I, Apostolou, M, Bnyan, R, Houacine, C, Elhissi, A and Yousaf, SS (2019) Paclitaxel-loaded Micro or Nano Transfersome Formulation into Novel Tablets for Pulmonary Drug Delivery via Nebulization. International Journal of Pharmaceutics. ISSN 0378-5173

Paclitaxelloaded Micro or Nano Transfersome Formulation into Novel Tablets for Pulmonary Drug Delivery.pdf - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (1MB) | Preview


A simplistic approach was conducted to manufacture novel paclitaxel (PTX) loaded protransfersome tablet formulations for pulmonary drug delivery. Large surface area presented by pulmonary system offer better target using anti-cancer drug deposition for localized effect in the lungs. Protransfersomes are dry powder formulations, whereas transfersomes are liquid dispersions containing vesicles generated from protransfersomes upon hydration. Protransfersome powder formulations (F1 - F27) (referred as Micro formulations based on transfersomes vesicles size post hydration) were prepared by employing phospholipid (Soya phosphatidylcholine (SPC)), three different carbohydrate carriers (Lactose monohydrate, LMH; Microcrystalline cellulose, MCC; and Starch), three surfactants (i.e. Span 80, Span 20 and Tween 80) in three different lipid phase to carrier ratios (i.e. 1:05, 1:15 and 1:25 w/w), with the incorporation of PTX as a model drug. Hydrophobic chain of SPC may enhance PTX solubility as well as its accommodation to improve entrapment and delivery via transfersome vesicles to the target site. Out of the 27 Micro protransfersome formulations, PTX-loaded LMH powder formulations F3, F6 and F9 (i.e. 1:25 w/w lipid phase to carrier ratio) exhibited an excellent powder flowability via angle of repose (AOR) and good compressibility index due to the smaller and uniform particle size and shape of LMH. Following hydration, these formulations also showed smaller volume median diameter (VMD) in micrometres (5.65 ± 0.85 - 6.76 ± 0.61 µm) and PTX entrapment of 93 - 96%. Hydrated transfersome formulations (F3, F6 and F9) were converted into Nano size via probe sonication and referred as Nano formulations. These Nano formulations were converted into dry powder via spray drying (SD) (F3NSD, F6NSD and F9NSD) or freeze drying (FD) (F3NFD, F6NFD and F9NFD). Post manufacture of protransfersome tablets (i.e. 9 formulations), quality control tests were conducted in accordance to British Pharmacopeia (BP). Only Micro formulations protransfersome tablets (i.e. F3, F6 and F9) passed the uniformity of weight test, exhibited high crushing strength and tablet thickness when compared to SD or FD protransfersome tablets. Micro protransfersome formulations (i.e. F3, F6 and F9) into tablets demonstrated shorter nebulization time and high output rate using Ultrasonic nebulizer as compared to Vibrating mesh nebulizer (i.e. Omron NE U22). Based on formulations, characterizations and nebulizer performance; Micro protransfersome tablet formulations F3, F6 and F9 (i.e. 1:25 w/w) and Ultrasonic nebulizer was found to be a superior combination with enhanced output efficiency. Moreover, PTX-loaded F3, F6 and F9 tablet formulations (10%) were identified as toxic (60, 68 and 67% cell viability) to cancer MRC-5 SV2 (i.e. immortalized human lung cells) while safe to MRC-5 (normal lung fibroblast cells) cell lines.

Item Type: Article
Uncontrolled Keywords: 1115 Pharmacology and Pharmaceutical Sciences
Subjects: R Medicine > RM Therapeutics. Pharmacology
Divisions: Pharmacy & Biomolecular Sciences
Publisher: Elsevier
Related URLs:
Date Deposited: 17 Dec 2019 11:44
Last Modified: 13 Oct 2021 14:01
DOI or ID number: 10.1016/j.ijpharm.2019.118919
URI: https://researchonline.ljmu.ac.uk/id/eprint/11922
View Item View Item